Intervention Review

You have free access to this content

Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection)

  1. Maite Vallejo*,
  2. Pedro PA Reyes

Editorial Group: Cochrane Heart Group

Published Online: 16 JUL 2008

Assessed as up-to-date: 12 SEP 2010

DOI: 10.1002/14651858.CD004102.pub2

Database Title

Additional Information

How to Cite

Vallejo M, Reyes PPA. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD004102. DOI: 10.1002/14651858.CD004102.pub2.

Author Information

  1. Juan Badiano No. 1. Col. Seccion XVI, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan, Mexico

*Maite Vallejo, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1. Col. Seccion XVI, Tlalpan, C.P. 14080, Mexico. maite_vallejo@yahoo.com.mx.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 16 JUL 2008

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (59K)Standard (230K)Full (251K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Rodriguez-Coura 1997 {published data only}
  • Rodriguez Coura J, De Abreu LL, Percy H, Willcox F, Petana W. A controlled comparative study using benznidazole, nifurtimox and placebo in chronic Chaga's disease patients, in a field area with interrupted transmission: I. preliminary evaluation [Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissäo interrompida: I. avaliaçäo preliminar]. Revista da Sociedade Brasileira de Medicina Tropical 1997;30:139-44.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Braga 2000 {published data only}
  • Braga MS, Lauria-Pires L, Argalaraz ER, Nascimento RJ, Teixeira ARL. Persistent infection in chronic chagas disease patients treated with anti-trypanosoma cruzi nitroderivatives. Revista do Instituto de Medicina Tropical de Sao Paulo 2000;42:157-61.
Cancado 2002 {published data only}
  • Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de Sao Paulo 2002;44:29-37.
Fabro 2000 {published data only}
  • Fabro de SD, Arias E, Streiger M, Placenza M, Ingraramo M, Del Barco M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated Chagasic patients. Revista do Instituto de Medicina Tropical de Sao Paulo 2000;42:99-109.
Lauria-Pires 2000 {published data only}
  • Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. American Journal of Tropical Medicine & Hygiene 2000;63(3-4):111-8.
Viotti 1994 {published data only}
  • Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas´ disease with benznidazole: clinical and serological evolution of patients with long-term follow-up. American Heart Journal 1994;127:151-62.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Marin-Neto 2008 {published data only}
  • Marin-Neto JA, Rassi A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal 2008;156(1):37-43.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Barretti 1990
  • Barretti AC, Serro Azul LG, Mady C, Ianni BM, De Brito Vianna C, Belloti C, et al. Indeterminate form of Chagas' disease. A polymorphic disease [Forma indeterminada da doenca de chagas: Uma doenca polimorfica]. Arquivos Brasileiros de Cardiologia 1990;55:347-53.
Brener 1975
  • Brener Z. Chemotherapy of Trypanosoma cruzi infection. Archives of Pharmacology 1975;13:13-44.
Cecere 1999
  • Cecere MC, Castañera MB, Canale DM, Chuit R, Gurtler RE. Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural northwestern Argentina. Revista Panamericana de Salud Publica 1999;5:392-99.
Chagas 1909
  • Chagas C. Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n.gen., n.sp., ajente etiolojico de nova entidade morbida do homem. Memórias do Instituto Oswaldo Cruz 1909;1:159-218.
Cochrane Heart Group
  • Cochrane Heart Group. Preferred method for handling continuous variables. http://www.heart.cochrane.org/Files/Handling%20continuous%20variables.pdf (accessed June 2005).
Coura 2009
de Andrade 1996
  • de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(9039):1407-13.
Dias-Contijo 1999
Follman 1992
Grant 1989
  • Grant Y, Gold JW, Witter M, Tanowotz HB, Nathan C, Mayer K. Transfusion-associated acute Chagas diseases acquired in the United States. Annals of Internal Medicine 1989;111:849.
Harry 2000
Higgins 2009
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
Kraus 2009
  • Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, Buckner FS, et al. Rational modification of a candidate cancer drug for use against Chagas disease. Journal of Medicinal Chemistry 2009;52(6):1639-47.
Kubata 2002
  • Kubata BK, Kabututu Z, Nozaki T, Munday CJ, Fukuzumi S, Ohkubo K, et al. A key role for old yellow enzyme in the metabolism of drugs by Tripanosoma cruzi. Journal of Experimental Medicine 2002;196:1241-51.
Laucella 2009
  • Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clinical Infectious Diseases 2009;49(11):1675-84.
Mady 2008
Marin-Neto 2009
  • Marin-Neto JA, Rassi JA, Avezum JA, Mattos AC, Rassi A. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Memorias do Instituto Oswaldo Cruz 2009;104(Suppl 1):319-24.
Monteón-Padilla 1995
  • Monteón-Padilla V, Guzman-Bracho C, Floriani-Verdugo J, Ramos-Echavaria A, Velazco-Castrejón O, Reyes-López PA. Serological diagnosis of Chagas disease: self-sufficiency and interlaboratory concordance [Diagnóstico serológico de la enfermedad de Chagas: autosuficiencia y concordancia interlaboratorios]. Salud Publica de Mexico 1995;37:232-5.
Monteón-Padilla 1999
  • Monteón-Padilla VM, Hernández-Becerril N, Guzmán-Bracho C, Rosales-Encina JL, Reyes-López PA. American Trypanosomiasis (Chagas' disease) and blood banking in Mexico city: seroprevalence and its potential tranfusional transmission risk. Archives of Medical Research 1999;30:393-8.
Moretti 1998
  • Moretti E, Cervetta L, Basso B, Castro I, Santamarina N. Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens [Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi]. Boletin Chileno de Parasitologia 1998;53:3-9.
Nickerson 1989
  • Nickerson P, Our P, Schruder ML, Sekla L, Johnston JB. Transfusion-associeted Trypanosoma cruzi infection in a non-endemic area. Annals of Internal Medicine 1989;111:851.
Oliveira-Filho 1989
Pinto 1995
  • Pinto Dias JC. Historia natural da doenca de Chagas. Arquivos Brasileiros de Cardiologia 1995;65:359-65.
Rassi 2007
  • Rassi A, Luquetti AO, Rassi J. Specific treatment for Trypanosoma cruzi: Lack of efficacy of allopurinol in the human chronic phase of chagas disease. American Journal of Tropical Medicine and Hygiene 2007;76(1):58-61.
Rodriguez-Coura 2002
Rojas-de-Arias 1999
  • Rojas-de-Arias A, Ferro EA, Ferreira ME, Simancas LC. Chagas disease vector control through different intervention modalities in endemic localities of Paraguay. Bulletin of the World Health Organization 1999;77:331-9.
Schmunis 1994
  • Schmunis GA. American tripanosomiasis as a public health problem. Chagas' disease and the nervous system. Washington DC: Pan American Health Organization, World Health Organization, 1994:3-29.
Schmunis 1999
  • Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Memorias do Instituto Oswaldo Cruz 1999;94(Suppl 1):93-101.
Schofield 1999
Segura 1994
  • Segura MA, Molina de Raspi E, Basombrio MA. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Memorias do Instituto Oswaldo Cruz 1994;89:213-6.
Sosa 1998
  • Sosa S, Segura EL, Mariano A, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. American Journal of Tropical Medicine & Hygiene 1998;59:526-9.
Stoppani 1999
  • Stoppani AOM. The chemotherapy of Chagas disease [Quimioterapia de la enfermedad de Chagas Quimioterapia de la enfermedad de Chagas]. Medicina 1999;59(Suppl 2):147-65.
Tanowitz 1992
  • Tanowitz HB, Morris SA, Factor SA, Weiss LM, Wittner M. Parasitic disease of the heart I: acute and Chronic Chagas' disease. Cardiovascular Pathology 1992;1:7-15.
Urbina 1999
  • Urbina JA. Parasitological cure of Chagas disease: is it possible? Is it relevant?. Memorias do Instituto Oswaldo Cruz 1999;94(Suppl 1):349-55.
Urbina 2009
  • Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Memorias do Instituto Oswaldo Cruz 2009;104(Suppl 1):311-8.
Villar 2002
  • Villar JC, Villar LA, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: ]
WHO 1991
  • World Health Organisation. Control of Chagas' disease. Report of a WHO expert committee. WHO Technical report series No. 811. Geneva: World Health Organisation, 1991.
Yun 2009
  • Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-Year experience of Medecins Sans Frontieres. PLoS Neglected Tropical Diseases 2009;3(7):e488.
View Full Article (HTML) Summary (59K)Standard (230K)Full (251K)